{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:30:20Z","timestamp":1693618220669},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2012.01.003","type":"journal-article","created":{"date-parts":[[2012,2,18]],"date-time":"2012-02-18T11:30:31Z","timestamp":1329564631000},"page":"913.e5-913.e8","source":"Crossref","is-referenced-by-count":9,"title":["Acute Central Retinal Artery Occlusion Treated with Intravenous Recombinant Tissue Plasminogen Activator"],"prefix":"10.1016","volume":"21","author":[{"given":"Richard J.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardik","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Robeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0002-9394(99)00359-1","article-title":"Aggressive systematic treatment for central retinal artery occlusion","volume":"128","author":"Rumelt","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archopht.1982.01030040563002","article-title":"Ocular neovascularization with retinal vascular occlusion. II. Occurrence in central and branch retinal artery occlusion","volume":"100","author":"Hayreh","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib3","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/S0161-6420(95)30758-0","article-title":"Efficacy of anterior chamber paracentesis and carbogen in treating acute nonarteritic central retinal artery occlusion","volume":"102","author":"Atebara","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archopht.121.10.1377","article-title":"Eye EAGfLit. Evaluation of minimally invasive therapies and rationale for a prospective randomized trial to evaluate selective intra-arterial lysis for clinically complete central retinal artery occlusion","volume":"121","author":"Mueller","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajo.2005.03.038","article-title":"Central retinal artery occlusion: Visual outcome","volume":"140","author":"Hayreh","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.1995.03530130023023","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)","volume":"274","author":"Hacke","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib8","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib9","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.STR.0000227191.01792.e3","article-title":"Group JACTJ-A. Alteplase at 0.6 mg\/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (j-act)","volume":"37","author":"Yamaguchi","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1212\/WNL.0b013e3181dad5a6","article-title":"Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia","volume":"74","author":"Chernyshev","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0161-6420(80)35283-4","article-title":"Central retinal artery occlusion and retinal tolerance time","volume":"87","author":"Hayreh","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2008-1045968","article-title":"Thrombolytic treatment of retinal arterial occlusions with plasminogen activator [in German]","volume":"198","author":"Bertram","year":"1991","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/archopht.1995.01100090016007","article-title":"Peripheral thrombolytic therapy for central retinal artery occlusion. CRAO Study Group","volume":"113","author":"Mames","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib15","first-page":"287","article-title":"Fibrinolysis with rTPA in acute retinal arterial occlusion [in Spanish]","volume":"75","author":"Cilveti Puche","year":"2000","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib16","first-page":"1234","article-title":"Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion","volume":"120","author":"Kattah","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib17","first-page":"25","article-title":"Systemic thrombosis in central retinal artery occlusion\u2014case report [in Romanian]","volume":"48","author":"Diaconu","year":"2004","journal-title":"Oftalmologia"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib18","first-page":"245","article-title":"Thrombolysis in central retinal artery occlusion using alteplase [in Czech]","volume":"64","author":"Mach","year":"2008","journal-title":"Cesk Slov Oftalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ajo.2008.06.016","article-title":"Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion","volume":"146","author":"Hattenbach","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib20","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/STROKEAHA.107.505404","article-title":"Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: The Johns Hopkins Hospital experience","volume":"39","author":"Aldrich","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNO.0b013e31814b1f66","article-title":"Thrombolysis for central retinal artery occlusion","volume":"27","author":"Biousse","year":"2007","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2012.01.003_bib22","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1161\/STROKEAHA.109.552547","article-title":"Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: A metaanalysis","volume":"40","author":"Lansberg","year":"2009","journal-title":"Stroke"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305712000055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305712000055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T21:21:02Z","timestamp":1543180862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305712000055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1052305712000055"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2012.01.003","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}